Why Is Retail Going Gaga Over INTS Stocks Today?

• In heavily pretreated patients with advanced disease having over 20 different types of cancer who had progressed following multiple prior lines of therapy, intratumoral INT230-6 achieved a disease control rate of 75%.
• In patients with metastatic sarcoma receiving only INT230-6, the median overall survival was 21.3 months, the company noted.
• CEO Lewis H. Bender said that the company has initiated randomized controlled studies, including a late-stage study in sarcoma.
   

Shares of Intensity Therapeutics, Inc. (INTS) jumped 282% on Thursday morning after the company announced the publication of positive data from a study of INT230-6 in the treatment of metastatic and refractory cancers.

In heavily pretreated patients with advanced disease having over 20 different types of cancer who had progressed following multiple prior lines of therapy, intratumoral INT230-6 achieved a disease control rate of 75% and a median overall survival of 11.9 months in the trial, the company said.

In patients with metastatic sarcoma receiving only INT230-6, the median overall survival was 21.3 months, the company noted. In a clinical trial, measuring the median overall survival is one way to assess the effectiveness of a new treatment.

INT230-6 induced a qualitative decrease in proliferating cancer cells in injected tumors, and pharmacokinetic results showed that greater than 95% of the active cytotoxic agents remained in the injected tumors, Intensity Therapeutics said.

Furthermore, 15 of 64 patients in the trial survived for more than 21 months, the company noted.

What Did Company Executives Say?

“Given the drug's mechanism of action and the data reported in this paper from over 20 types of metastatic solid cancers, such as breast, sarcoma, pancreatic, lung, and head and neck, we believe the study results show the potential of INT230-6 to achieve clinical benefit for metastatic patients of multiple cancer types with or without the use of radiation, systemic drugs or immunotherapy.”
Lewis H. Bender, CEO, Intensity Therapeutics

The CEO added that the company has initiated randomized controlled studies, including a late-stage study in sarcoma. This rare cancer originates in the body's connective tissues, such as bone, muscle, fat, and cartilage.

INT30-6 consists of two proven, potent anti-cancer agents, cisplatin and vinblastine sulfate, and a diffusion and cell penetration enhancer molecule. In addition to local disease control and direct tumor killing, it causes a release of a bolus of neoantigens specific to the malignancy, leading to immune system engagement and systemic anti-tumor effects.

How Did Stocktwits Users React?

On Stocktwits, retail sentiment around INTS stock jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.

INTS stock is down 42% this year and approximately 67% over the past 12 months. 

Read also: Sensei Biotherapeutics Halts Lead Drug Development, Explores Sale Or Merger Options

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on